Most Read Articles
Audrey Abella, 09 Jun 2017
Maintenance therapy with olaparib significantly improved progression-free survival (PFS) and patient-centred benefits in patients with germline BRCA-mutated, platinum-sensitive relapsed serous ovarian cancer (gBRCAm PSR SOC) compared with placebo, according to the SOLO* 2 trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.
Elvira Manzano, 14 Jun 2017
The oral PARP inhibitor olaparib significantly improved progression-free survival (PFS) in women with BRCA-positive, HER2-negative breast cancer compared with standard chemotherapy in the phase III OlympiAD* trial, ushering in a new era of hope in BRCA-mutated breast cancer.
Pearl Toh, 01 Aug 2016
Understanding biomarkers predictive of treatment outcomes or response can help inform treatment decisions and personalize care for advanced prostate cancer patients, suggested an expert at the recent Urological Association of Asia Annual Congress (UAA 2016) held in Singapore.
Audrey Abella, 13 Jun 2017
A psychological intervention, Conquer Fear, may help alleviate fear of cancer recurrence (FCR) in cancer survivors, according to a study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.

Presepsin may help detect febrile neutropaenia during chemotherapy

16 Mar 2017

Plasma presepsin appears to be an effective diagnostic marker for febrile neutropaenia (FN) in patients on massive chemotherapy, according to a Japanese study.

Derived from the cluster of differentiation 14 (CD14) protein, presepsin has been used for the prognosis and early diagnosis of severe sepsis. “While this molecule is a prompt and specific marker for bacterial infections, its reliability in FN is not yet confirmed,” said researchers, adding that the severe neutropaenia observed during massive chemotherapy may cause false-negative results for this marker.

To determine whether presepsin levels increase with bacteraemia in the setting of severe neutropaenia, researchers included patients with haematologic malignancy or bone marrow failure who developed severe neutropaenia after undergoing either conventional induction chemotherapy or haematopoietic stem cell transplantation (HSCT).

Patients were divided into two groups: those who were diagnosed with bacteraemia during a period of neutropaenia (FN group) and a control group consisting of patients with who had no febrile episodes for 3 weeks after chemotherapy but did not receive antimicrobial treatment (afebrile neutropaenia [AFN] group). A neutropaenic period was defined as a white blood cell (WBC) count <1,000/μL or neutrophil count <500/μL.

Plasma presepsin levels of FN patients were measured every 2 to 3 days and values compared with those of the AFN group. Outcome measures included presepsin levels at baseline and at FN onset, presepsin increase rate at FN onset, and onset/baseline ratio.

Eleven episodes of FN (with six gram-negative and five gram-positive pathogens identified in blood cultures) were reported and analysed in detail. Plasma presepsin levels were strongly associated with CRP levels (r=0.61; p<0.01), but not with the absolute WBC count (r=−0.19; p=0.19), absolute neutrophil count (r=−0.11; p=0.41) or absolute monocyte count (r=−0.12; p=0.40).

The presepsin cutoff value, which was set at 314 pg/mL, detected FN onset in nine of 11 cases, with the two undetected cases caused by Bacillus species.

On evaluating for renal function, researchers found no association between plasma presepsin levels and serum creatinine (r=0.08, p=0.55) or estimated glomerular filtration rate (r=0.21, p=0.12).

Although FN is a common infectious complication in chemotherapy, patients with haematologic malignancies who develop FN carry a higher risk of mortality.

In light of study findings, researchers posited that plasma presepsin may be a reliable marker of FN even in this population who has very low WBC counts. Closer monitoring of presepsin levels may be of benefit in the early diagnosis of FN, said researchers.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Audrey Abella, 09 Jun 2017
Maintenance therapy with olaparib significantly improved progression-free survival (PFS) and patient-centred benefits in patients with germline BRCA-mutated, platinum-sensitive relapsed serous ovarian cancer (gBRCAm PSR SOC) compared with placebo, according to the SOLO* 2 trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.
Elvira Manzano, 14 Jun 2017
The oral PARP inhibitor olaparib significantly improved progression-free survival (PFS) in women with BRCA-positive, HER2-negative breast cancer compared with standard chemotherapy in the phase III OlympiAD* trial, ushering in a new era of hope in BRCA-mutated breast cancer.
Pearl Toh, 01 Aug 2016
Understanding biomarkers predictive of treatment outcomes or response can help inform treatment decisions and personalize care for advanced prostate cancer patients, suggested an expert at the recent Urological Association of Asia Annual Congress (UAA 2016) held in Singapore.
Audrey Abella, 13 Jun 2017
A psychological intervention, Conquer Fear, may help alleviate fear of cancer recurrence (FCR) in cancer survivors, according to a study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.